[In Context] Does neurology need a faster FDA?
The Lancet Neurology
The FDA's neurology division has been reported as the slowest of all the agency's divisions at approving new drugs. If this is true, the economic impact could be affecting drug innovation and ultimately patient care. But what, if anything, needs to be done? Adrian Burton investigates.
Original Article: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70162-0/fulltext?rss=yes
Júlio Pereira
www.weneuro.com
www.linkedin.com/in/juliommais
lattes.cnpq.br/7687651239699170
Consultório (11)3141-9550/3141-9553
No comments:
Post a Comment